Patent intelligence · US
US 8906964
Methods of administering compositions comprising docosapentaenoic acid
Methods of administering compositions comprising docosapentaenoic acid
Patent details — US 8906964
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 9, 2014
- Expiration
- Dec 4, 2034
- Applicant
- MATINAS BIOPHARMA INC.
- Claims
- 21
- CPC classes
- A61K, A61K31/201, A61K31/202, A61K31/232
Quick answer
US 8906964 (Methods of administering compositions comprising docosapentaenoic acid) is held by MATINAS BIOPHARMA INC.. Status: granted. Granted Dec 9, 2014. Expires Dec 4, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MATINAS BIOPHARMA INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/201, A61K31/202, A61K31/232, A61K31/40, A61K9/4825
More from MATINAS BIOPHARMA INC.
Related pharmaceutical patents in our USPTO index.
-
US 12409227
Cochleates made with soy phosphatidylserine
granted -
US 11964019
Cochleates made with soy phosphatidylserine
granted -
US 11389407
Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
granted -
US 11123295
Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections
granted -
US 10716860
Cochleates made with soy phosphatidylserine
granted -
US 10058521
Omega-3 pentaenoic acid compositions and methods of use
granted -
US 9775907
Cochleates made with soy phosphatidylserine
granted
Related coverage
Frequently asked questions
What is US patent 8906964?
US 8906964 (Methods of administering compositions comprising docosapentaenoic acid) is held by MATINAS BIOPHARMA INC.. Status: granted. Granted Dec 9, 2014. Expires Dec 4, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8906964?
MATINAS BIOPHARMA INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 8906964 expire?
Our index shows an expiration date of Dec 4, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.